GLP-1 Lab Monitoring: Baseline and Follow-Up Blood Work

Summary: Get a baseline A1C, CMP with eGFR, lipid panel, and TSH before your first dose. Recheck A1C and kidney function at 3 months in type 2 diabetes and after any dose escalation, with full panels at 6 and 12 months.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GLP-1 lab monitoring is the boring part of weight loss medicine that quietly catches the things that hurt people. Skip it and you miss undiagnosed diabetes, a borderline kidney, a thyroid nodule the prescriber should have asked about. Do it right and you have a reference point for every result that follows. The baseline panel takes one blood draw. The follow-up schedule is short. Both are nailed down by the FDA labels for Wegovy and Zepbound and by mainstream diabetes practice.

This page lays out exactly what to order before your first injection, what to recheck and when, and what each value is actually telling you.

The baseline panel before your first dose

Five tests cover the standard of care for almost every adult starting a GLP-1. Add to this list only when a specific risk factor is present.

The Wegovy and Zepbound labels both carry a boxed warning for thyroid C-cell tumors based on rodent studies and contraindicate use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) ^[1][2]. A baseline TSH does not rule out MTC on its own, but it forces the conversation. Ask about family history before the needle goes near your skin.

When to add tests

The five-test panel is the floor. These additions earn their place when the clinical situation calls for them.

• Urine albumin-to-creatinine ratio (UACR) if you have type 2 diabetes or known kidney disease. The ADA Standards of Care recommend annual UACR screening in diabetes, and it pairs naturally with the eGFR you are already ordering ^[4].
• Lipase and amylase if you have a prior history of pancreatitis. The GLP-1 class carries a small but real pancreatitis signal in trial data. Baseline enzymes give you a comparator if abdominal pain develops.
• Fasting insulin and C-peptide if the diabetes type is uncertain or you want to quantify insulin resistance. Useful, not mandatory.
• Vitamin D if you have not measured it in the past year. Rapid weight loss accelerates bone turnover and a deficient baseline is worth catching.
• Calcitonin or thyroid ultrasound only if a thyroid nodule is palpable or there is a personal or family history of thyroid cancer.

There is no value in routinely ordering twenty tests. Each extra panel adds false positives and patient anxiety without changing management for the average person starting Wegovy or Zepbound.

The follow-up schedule

Monitoring frequency depends on whether you are using a GLP-1 for type 2 diabetes, for weight loss in someone metabolically healthy, or in a patient with baseline kidney impairment. Below is what mainstream practice looks like when matched to the FDA label language and ADA guidance.

The American Diabetes Association recommends checking HbA1c at least twice a year if you are at goal and quarterly if therapy has changed or you are not at goal ^[4]. That maps cleanly onto a GLP-1 titration schedule: every dose increase is a therapy change, every plateau on a maintenance dose buys you a six-month interval.

Weight tracking is weekly to monthly, not lab-based, and you record it at home. Once a week at the same time of day under the same conditions beats daily weighing. The number is noise on any single day and signal across four weeks.

What changes during dose titration

The titration phase is where most lab problems show up because it is when GI side effects are at their worst. Nausea, vomiting, and reduced intake all pull on the kidney. The Wegovy label specifically warns about acute kidney injury secondary to volume depletion in patients with renal impairment ^[1]. The pattern is dehydration first, prerenal AKI second, and a panicked patient third. Bringing in a CMP four to eight weeks after each dose escalation in patients with eGFR under 60 catches it before it becomes a hospital admission.

For a patient with normal baseline kidney function and no severe GI side effects, that 4-to-8-week draw is not required. Symptom-driven testing is reasonable when the baseline was clean.

What each value is actually telling you

HbA1c

Your three-month average glucose. The number you are tracking with the most clinical weight.

• Under 5.7%: normal
• 5.7 to 6.4%: prediabetes
• 6.5% and above: diabetes

A patient who shows up for "weight loss" with an A1C of 7.4% has type 2 diabetes. That changes the conversation about insurance coverage (Ozempic and Mounjaro for diabetes, Wegovy and Zepbound for obesity), the monitoring schedule, and the question of whether other diabetes medications need to be reduced. GLP-1 therapy commonly drops A1C by 1 to 2 percentage points; if you are also on a sulfonylurea or insulin, expect a hypoglycemia discussion at the first follow-up.

Recheck A1C every 3 months in type 2 diabetes during titration, then every 6 months once stable. In a non-diabetic patient on a GLP-1 for weight, annual is enough.

Kidney function: creatinine and eGFR

Creatinine is a waste product the kidneys filter; eGFR is the calculated filtration rate based on creatinine, age, and sex. A normal eGFR is over 60 mL/min/1.73 m^2. Below 60 is chronic kidney disease (CKD); below 30 is severe and changes how prescribers think about every drug you take.

GLP-1s do not directly damage kidneys at therapeutic doses. They can hurt the kidney indirectly through volume depletion when you cannot keep fluids down. The Wegovy and Ozempic labels both list acute kidney injury as a postmarketing adverse reaction associated with severe nausea, vomiting, or diarrhea ^[1][3]. The defense is monitoring plus aggressive rehydration whenever GI symptoms persist beyond a day or two.

A modest eGFR dip during titration in a patient who is eating less and drinking less is usually prerenal. Rehydrate, recheck in a week, and the number typically returns. A sustained decline or a baseline eGFR under 30 deserves nephrology input.

Liver enzymes: AST and ALT

GLP-1 therapy generally improves liver enzymes because it improves hepatic steatosis. Studies of semaglutide and tirzepatide in NASH and MASLD show meaningful drops in ALT alongside weight loss. The exception is a small transient bump in the first weeks as liver fat mobilizes; this resolves.

The threshold that matters: ALT or AST above 3 times the upper limit of normal. That is the standard pause-and-evaluate trigger in drug safety. Anything in that zone gets a call to the prescriber and usually a hold on the next dose until the cause is identified.

Lipid panel

GLP-1s improve lipid profiles, especially triglycerides. Tirzepatide in the SURMOUNT trials drove substantial triglyceride reduction at therapeutic doses. The number to flag at baseline is triglycerides over 500 mg/dL, which signals pancreatitis risk independent of any medication and is worth treating before or alongside GLP-1 initiation.

Recheck the lipid panel at 6 months and annually. It is one of the most satisfying labs to track on therapy because the numbers consistently move in the right direction.

TSH

A screening test, not a definitive thyroid evaluation. Above 4.0 to 5.0 mIU/L suggests hypothyroidism and warrants follow-up free T4 and consideration of levothyroxine. Below 0.4 suggests hyperthyroidism. Either result deserves further workup before you start, because thyroid dysfunction itself drives weight changes and confuses your assessment of whether the GLP-1 is working.

The TSH is also the practical hook for the MTC conversation. When the lab orders go in, the prescriber should be asking the family history question alongside it.

CBC

Not specific to GLP-1 monitoring. Useful because it catches anemia, occult infection, or platelet abnormalities that could complicate any chronic therapy. Not routinely repeated unless symptoms warrant.

CGM and home monitoring

A continuous glucose monitor (CGM) is overkill for most people on a GLP-1 for weight loss. It is genuinely useful in three situations.

1. Type 2 diabetes treated with a GLP-1 plus insulin or a sulfonylurea, where hypoglycemia risk is real and the CGM data drives dose decisions.
2. Patients curious about meal responses and willing to use the data to change behavior. The 10-day Libre or Dexcom Stelo packs are now over-the-counter in the US and cost roughly $50 to $90.
3. Brittle glucose control where a single A1C every three months is too coarse a signal.

For everyone else, the relevant home monitoring is simpler:

• Weekly weight at the same time of day
• Weekly blood pressure if you take antihypertensives, because weight loss commonly drops BP and your dose may need lowering
• Daily hydration awareness, especially during dose escalation
• A simple log of side effects and the dates they appeared

At-home finger-stick A1C kits exist and produce numbers in the right ballpark, but they are less accurate than a venous draw and they do not replace a CMP. They are a supplement, not a substitute.

Will a GLP-1 show up on a routine blood test?

A standard CMP, CBC, lipid panel, A1C, or TSH does not detect semaglutide, tirzepatide, or any other GLP-1 in the blood. There is no routine clinical assay for the drug itself, and labs do not screen for it as part of standard panels. Specialized mass spectrometry methods exist in research and forensic settings, but they are not what your PCP orders.

What does show up are the downstream effects: dropping A1C, improving triglycerides, sometimes a transient eGFR shift in a dehydrated patient. If a clinician asks whether you are on a GLP-1, tell them. It is not a question your blood will answer for you on a routine draw.

How to actually get these labs ordered

Three pathways work.

Through your telehealth GLP-1 provider. The better programs include baseline labs as part of onboarding and will reorder at 3 and 6 months. Ask up front: do you require baseline labs before prescribing, and do you order follow-up labs as part of the program? A provider that says "we do not require labs" is optimizing for conversion speed, not for your safety.

Through your primary care physician. The full baseline panel typically runs $0 to $75 with insurance and integrates with the rest of your care. This is the cleanest path if you already have a PCP relationship.

Direct lab ordering. Quest Health, Labcorp OnDemand, and similar services let you order panels online and walk into a draw station. Without insurance, expect $100 to $200 for the core panel. This works when your telehealth provider will not order labs and you do not want to wait for a PCP appointment.

The point of paying for labs is that you actually look at them. Pull the PDF, scroll to the values that are out of range, ask the prescriber what they mean for your dose. The cost is wasted if the report sits in an inbox.

Red flags that need attention before the next scheduled draw

These warrant a call to the prescriber within the week, not at the 3-month follow-up.

• Severe upper abdominal pain radiating to the back: rule out pancreatitis with lipase and amylase
• Yellowing of skin or eyes: check liver function and bilirubin
• Persistent vomiting that prevents you from holding down fluids: dehydration and kidney injury risk
• A new lump in the neck or persistent hoarseness: thyroid evaluation
• Significantly reduced urination: kidney function check
• Severe hypoglycemia, especially if you are on insulin or a sulfonylurea

None of these are common, but the FDA labels list every one of them as a known adverse event class for GLP-1 receptor agonists ^[1][2][3]. The point of monitoring is not paranoia. It is having a baseline so the call you make about a new symptom has data behind it.

Common questions about GLP-1 blood work

What blood tests do I need before starting a GLP-1?

HbA1c, comprehensive metabolic panel with eGFR, fasting lipid panel, TSH, and CBC. Add UACR in type 2 diabetes and lipase if you have a history of pancreatitis.

How often should I get labs while on Ozempic, Wegovy, Mounjaro, or Zepbound?

HbA1c every 3 months in type 2 diabetes, every 6 to 12 months for weight loss. Recheck a CMP at 3 and 6 months, then annually if stable. Weight monthly.

Will a GLP-1 show up on a routine blood test?

No. Standard panels do not detect semaglutide or tirzepatide directly. You will see downstream effects like a lower A1C or improved lipids, but not the drug itself.

Do I need a CGM with a GLP-1?

Only if you have type 2 diabetes on insulin or sulfonylureas, or you want detailed meal-response data. For most weight-loss patients without diabetes, periodic A1C is enough.

What lab check do I need at 3 months on a GLP-1?

HbA1c and a comprehensive metabolic panel covering kidney function, liver enzymes, and electrolytes. Add a lipid panel if you skipped it at the 3-month mark and want a midpoint reading.

Are the lab requirements different for compounded versus brand-name GLP-1?

No. The monitoring is based on the drug mechanism, not the manufacturer. Compounded semaglutide gets the same panel as brand Wegovy.

My kidney number dropped a little during titration. Should I worry?

A small eGFR dip during a phase of nausea and reduced fluid intake usually reflects dehydration, not direct kidney injury. Rehydrate, recheck in a week, and call your prescriber if the trend continues.

Can I monitor my GLP-1 progress at home?

Weekly weight, weekly blood pressure if relevant, a daily hydration check, and a side-effect log cover most of what home monitoring can do. Lab panels still need a venous draw.

Are there home tools for GLP-1 monitoring?

Useful options include a digital scale, an upper-arm blood pressure cuff, an OTC continuous glucose monitor like Stelo if your prescriber recommends it, and a simple weekly log.

What does the FDA label say about lab monitoring on Wegovy and Zepbound?

Both labels recommend assessing renal function in patients with renal impairment, watching for pancreatitis symptoms, and counseling on thyroid C-cell tumor risk. Neither mandates a fixed lab schedule for healthy adults.

The short version

Five tests before your first dose: HbA1c, CMP with eGFR, lipid panel, TSH, CBC. Add UACR in diabetes and lipase if you have a pancreatitis history. Recheck HbA1c and CMP at 3 months, full panel at 6 and 12 months, then annually. Pull the CMP earlier if you have baseline kidney impairment or severe GI side effects. Monthly weight. Symptom-driven testing for anything off-script. The FDA labels for Wegovy, Zepbound, and Ozempic give you the framework; the schedule above is what disciplined GLP-1 prescribing actually looks like.